Skip to contentO
OptimizeRx Corp
O
OPRXOptimizeRx Corp Q2 2023 · 10-Q
Revenue$13.82M$13.82M−1.1% vs Q2 2022 Net Income-$4.16M-$4.16MN/M vs Q2 2022 EPS Diluted-$0.24-$0.24N/M vs Q2 2022 Gross Profit$7,825,000−13.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
OptimizeRx Corp · CIK 1448431 · Engraved from SEC EDGAR
Operating Cash Flowderived-$2,369,000N/M Free Cash Flowderived-$2,388,976N/M Margins · derivedGross margin56.6%−7.7 pt vs Q2 2022
Operating margin-35.1%−7.1 pt vs Q2 2022
Net margin-30.1%−2.3 pt vs Q2 2022
ended Jun 30, 2023 · filed Aug 14, 2023 · 45 d after period end